drugset / Trial / NCT01129960
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Diabetic Neuropathic Pain (DNP) over a 15 week treatment phase.
Timeline
- Start
- 2010-11
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eslicarbazepine acetate | Unknown | 800 mg | — |
| Subject | Eslicarbazepine acetate | Unknown | 1200 mg | — |
| Subject | Eslicarbazepine acetate | Unknown | 1600 mg | — |